Expanded Access of Imvotamab (IGM-2323) in Patients With R/R NHL
NCT06331832 · Status: NO_LONGER_AVAILABLE · Type: EXPANDED_ACCESS
Last updated 2024-03-26
Summary
Expanded Access of Imvotamab (IGM-2323) in Patients with Relapsed/Refractory Non-Hodgkin Lymphomas from IGM-2323-001 clinical trial.
Conditions
- Relapsed/Refractory Non-Hodgkin Lymphomas
Interventions
- BIOLOGICAL
-
IGM2323
Imvotamab is a recombinant monoclonal antibody of the IgM kappa isotype that targets the human CD20 antigen. Its component J-chain is fused to a single chain Fv antibody fragment which targets human CD3ε.
Sponsors & Collaborators
-
IGM Biosciences, Inc.
lead INDUSTRY
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
Countries
- Australia
- South Korea
- Spain
Study Locations
More Related Trials
-
Rituximab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Large Cell Lymphoma
NCT00005631 ·Status: COMPLETED ·Phase: PHASE2
-
Lenalidomide Plus Rituximab Followed by Lenalidomide Versus Rituximab Maintenance for Relapsed/Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma.
NCT01996865 ·Status: COMPLETED ·Phase: PHASE3
-
Treatment of Relapsed Low-Grade or Follicular Lymphoma With Rituximab (Also Known as Rituxan, IDEC-C2B8, IDEC-102)
NCT00168740 ·Status: COMPLETED ·Phase: PHASE3
-
Large Fraction Radiation Therapy Combined With Lenalidomide, and Glofitamab in Refractory Relapsed DLBCL
NCT06651853 ·Status: RECRUITING ·Phase: PHASE2
-
Safety and Efficacy of IDEC-114 in Combination With Rituxan in the Treatment of Non-Hodgkin's Lymphoma
NCT00048555 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Cellular Immunotherapy for Relapsed or Refractory Lymphoma Data Collection
NCT06541327 ·Status: RECRUITING
-
Ibrutinib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Older Patients With Newly Diagnosed Mantle Cell Lymphoma
NCT01880567 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Bispecific Antibody-Based Salvage Therapy Followed by CAR-T ± ASCT in R/R Aggressive B-Cell Lymphoma
NCT06996132 ·Status: RECRUITING ·Phase: PHASE2
-
Rituximab Plus 2CdA in Patients With Advanced or Relapsed Mucosa Associated Lymphoid Tissue (MALT) Lymphoma
NCT00656812 ·Status: COMPLETED ·Phase: PHASE2
-
Rituximab Plus Lenalidomide for Patients With Relapsed / Refractory Indolent Non-Hodgkin's Lymphoma (Follicular Lymphoma and Marginal Zone Lymphoma)
NCT01938001 ·Status: COMPLETED ·Phase: PHASE3
-
Ibritumomab Tiuxetan (Zevalin)+ Rituximab Maintenance
NCT00582166 ·Status: TERMINATED ·Phase: PHASE2
-
Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy
NCT06834373 ·Status: RECRUITING ·Phase: PHASE2
-
QUILT-3.052: NANT Non-Hodgkin Lymphoma (NHL) Vaccine: Combination Immunotherapy in Subjects With Relapsed CD20-positive NHL
NCT03169790 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2
-
An Expanded Access Program to Provide Sugemalimab for the Treatment of Relapsed or Refractory Extranodal Natural Killer/T-Cell Lymphoma (R/R ENKTL)
NCT05131438 ·Status: NO_LONGER_AVAILABLE
-
Agatolimod Sodium, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Recurrent or Refractory Non-Hodgkin Lymphoma
NCT00438880 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Study of GNC-038 Injection in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
NCT05623982 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
A Study Comparing Maintenance Subcutaneous Rituximab With Observation Only in Participants With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma Who Had Responded to Rituximab-based Immunochemotherapy Induction and 2-year Maintenance With Subcutaneous Rituximab
NCT01461928 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Efficacy of Autologous NK Cell Adjuvant Therapy for Relapsed/Refractory Non-Hodgkin's B-cell Lymphoma
NCT05909098 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1/PHASE2
-
Rituximab Plus Lenalidomide in Patients With Mucosa Associated Lymphoid Tissue
NCT01611259 ·Status: COMPLETED ·Phase: PHASE2
-
Pegfilgrastim and Rituximab in Treating Patients With Untreated, Relapsed, or Refractory Follicular Lymphoma, Small Lymphocytic Lymphoma, or Marginal Zone Lymphoma
NCT01682044 ·Status: COMPLETED ·Phase: PHASE2
-
Radiolabeled Monoclonal Antibody Plus Rituximab With and Without Filgrastim and Interleukin-11 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
NCT00012298 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Study of ISB 1342, a CD38/CD3 Bispecific Antibody, in Subjects With Previously Treated Multiple Myeloma
NCT03309111 ·Status: COMPLETED ·Phase: PHASE1
-
Radiation Free Chemotherapy for Early Hodgkin Lymphoma
NCT04866654 ·Status: RECRUITING ·Phase: PHASE2
-
Clofarabine and Rituximab in Treating Patients With Relapsed Non-Hodgkin Lymphoma
NCT00691652 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
A Clinical Study of Injectable IMM0306 in Combination With Lenalidomide
NCT05771883 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1/PHASE2